The city of Miami Springs, Florida, currently has 5 active clinical trials seeking participants for Alzheimer's Disease research studies.
A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Psychosis Associated With Alzheimer's Disease
NCT06540833
Recruiting
This is a multicenter, randomized, double-blind, parallel-group, placebo-controlled, flexible-dose study evaluating the efficacy, safety, and tolerability of ITI-1284 compared with placebo in the treatment of psychosis in patients with AD.
Gender:
ALL
Ages:
55 years and above
Trial Updated:
02/19/2025
Locations: Clinical Site, Miami Springs, Florida
Conditions: Psychosis Associated With Alzheimer's Disease
Register for Updates
A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)
NCT05026866
Recruiting
The main purpose of this study is to evaluate the safety and efficacy of donanemab in participants with preclinical Alzheimer's Disease (AD). Approximately 800 additional participants will be enrolled in a 12-month addendum to assess safety of a different titration regimen.
Gender:
ALL
Ages:
Between 65 years and 80 years
Trial Updated:
02/18/2025
Locations: South Florida Research Phase I-IV, Miami Springs, Florida
Conditions: Alzheimer Disease
Register for Updates
A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1)
NCT05511363
Recruiting
This is a Phase 3, 38-week, randomized, double-blind, placebo-controlled, multicenter, outpatient study in subjects with psychosis associated with Alzheimer's Disease. The primary objective of the study is to evaluate relapse prevention in subjects with psychosis associated with Alzheimer's Disease treated with KarXT compared to placebo. The secondary objectives of the study are to evaluate the time from randomization to discontinuation for any reason and safety and tolerability in subjects wit... Read More
Gender:
ALL
Ages:
Between 55 years and 90 years
Trial Updated:
02/18/2025
Locations: Ocean Blue Medical Research Center Inc, Miami Springs, Florida +1 locations
Conditions: Psychosis Associated With Alzheimer's Disease
Register for Updates
Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)
NCT05980949
Recruiting
This is a Phase 3 global, multicenter, 52-week, open-label extension (OLE) rollover study for subjects completing study CN012-0026, CN012-0027 or CN012-0056. Subjects (randomized or non-randomized) who complete the 38-week CN012-0026 study, 14-week CN012-0027 study or 14-week CN012-0056 study will be eligible to enroll in CN012-0028. The primary objective of the study is to assess the long-term safety and tolerability of KarXT in subjects with psychosis associated with Alzheimer's Disease.
Gender:
ALL
Ages:
Between 55 years and 90 years
Trial Updated:
02/18/2025
Locations: Ocean Blue Medical Research Center Inc, Miami Springs, Florida
Conditions: Psychosis Associated With Alzheimer's Disease
Register for Updates
Study to Evaluate the Efficacy, Safety, and Tolerability of an Anti-MTBR Tau Monoclonal Antibody (BMS-986446) in Participants With Early Alzheimer's Disease
NCT06268886
Recruiting
The purpose of this study is to assess the effectiveness, safety, and tolerability of BMS-986446 an Anti-MTBR Tau Monoclonal Antibody in participants with Early Alzheimer's Disease.
Gender:
ALL
Ages:
Between 60 years and 80 years
Trial Updated:
02/10/2025
Locations: South Florida Research Phase I-IV, Inc, Miami Springs, Florida
Conditions: Alzheimer Disease, Early Onset
Register for Updates